ETYQA

Post-LOE

estradiol and norethindrone acetate

Aurobindo Pharma

ANDAORALTABLET

Approved

Jun 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ETYQA (estradiol and norethindrone acetate) by Aurobindo Pharma is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause () treatment of moderate to severe symptoms of vulvar, vaginal atrophy due to menopause () limitations of use:, vaginal atrophy due to menopause and 3 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

Estrogen Receptor Agonists

Pharmacologic Class:

Estrogen

Indications (5)

a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause () Treatment of Moderate to Severe Symptoms of Vulvar Vaginal Atrophy due to Menopause () Limitations of Use:

Worked on ETYQA at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.